Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Odalasvir +/- Simeprevir and Dabigatran
NCT02945020Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of odalasvir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration at Day 26 and Area Under the Plasma Concentration-Time Curve at Day 26. Started Nov 2016; status: completed.
02
Drugs
odalasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02945020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945020.